482 related articles for article (PubMed ID: 19615696)
1. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
[TBL] [Abstract][Full Text] [Related]
2. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Zipoli V; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Lepore V; Livrea P; Comi G; Amato MP;
Ann Neurol; 2009 Oct; 66(4):513-20. PubMed ID: 19847899
[TBL] [Abstract][Full Text] [Related]
3. New natural history of interferon-beta-treated relapsing multiple sclerosis.
Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP
Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502
[TBL] [Abstract][Full Text] [Related]
4. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
[TBL] [Abstract][Full Text] [Related]
5. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
[TBL] [Abstract][Full Text] [Related]
6. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
[TBL] [Abstract][Full Text] [Related]
7. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.
O'Rourke K; Walsh C; Antonelli G; Hutchinson M
Mult Scler; 2007 Apr; 13(3):336-42. PubMed ID: 17439902
[TBL] [Abstract][Full Text] [Related]
8. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: an Italian cohort study.
Russo P; Paolillo A; Caprino L; Bastianello S; Bramanti P
J Eval Clin Pract; 2004 Nov; 10(4):511-8. PubMed ID: 15482413
[TBL] [Abstract][Full Text] [Related]
10. Interferon beta treatment of MS in the daily clinical setting: a 3-year post-marketing study.
Onesti E; Bagnato F; Tomassini V; Volante G; Denaro F; Frontoni M; Millefiorini E; Pozzilli C; Fieschi C
Neurol Sci; 2003 Dec; 24(5):340-5. PubMed ID: 14716530
[TBL] [Abstract][Full Text] [Related]
11. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
12. [Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients].
Patrucco L; Rojas JI; Cristiano E
Rev Neurol; 2010 May; 50(9):529-32. PubMed ID: 20443171
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
14. The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy.
Trojano M; Paolicelli D; Zimatore GB; De Robertis F; Fuiani A; Di Monte E; Livrea P
Neurol Sci; 2005 Dec; 26 Suppl 4():S179-82. PubMed ID: 16388354
[TBL] [Abstract][Full Text] [Related]
15. Measures in the first year of therapy predict the response to interferon beta in MS.
Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
[TBL] [Abstract][Full Text] [Related]
16. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
[TBL] [Abstract][Full Text] [Related]
17. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
18. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands.
Bosca I; Villar LM; Coret F; Magraner MJ; Simó-Castelló M; Alvarez-Cermeño JC; Casanova B
Mult Scler; 2010 Jul; 16(7):810-5. PubMed ID: 20538705
[TBL] [Abstract][Full Text] [Related]
19. [Interferon-beta response in multiple sclerosis associated with pre-treatment disability].
Fernandez-Fernandez O; Fernandez-Sanchez VE; Mayorga C; Guerrero-Fernandez M; Leon A; Tamayo-Toledo JA; Alonso A; Romero F; Leyva L; Luque G; de Ramon E
Rev Neurol; 2006 Sep 16-30; 43(6):322-9. PubMed ID: 16981161
[TBL] [Abstract][Full Text] [Related]
20. Glypican 5 is an interferon-beta response gene: a replication study.
Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A
Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
